DxS Ltd. (DxS) has appointed Jane Papadaki-Markley as sales and marketing director of the company as it expands in North America. Jane is based in California and will be responsible for the continued expansion of DxS’ tumour mutation analysis products in the US and Canada. Jane joins DxS from Agendia, Inc, where she was senior director of sales and marketing.
She previously worked for Focus Diagnostics/Quest for over 20 years in a wide-ranging role encompassing sales and marketing, technical advisory and business development.
Stephen Little, chief executive officer of DxS, said: “The demand for our tumour mutation kits has increased dramatically on a global scale and we have to ensure that we have skilled people available to support this growth. North America and Canada are particularly key markets and Jane will bring invaluable industry knowledge, specialised and relevant experience, and enthusiasm to DxS. She is ideally placed to provide insight and advice about our products to our North American market over the coming months.”